- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.04. | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of AlzeCure Pharma AB | 205 | GlobeNewswire | With effect from May 02, 2024, the subscription rights in AlzeCure Pharma AB
will be traded on First North Growth Market. Trading will continue up until and
including May 14, 2024.
Instrument: Subscription... ► Artikel lesen | |
| 25.04. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - March 2024 | 434 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / April 25, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - March... ► Artikel lesen | |
| 25.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 25.04.2024 | 175 | Xetra Newsboard | Das Instrument AB2 NL0011540547 ABN AMRO BANK DR/EO1 EQUITY wird cum Kapitalmassnahme gehandelt am 25.04.2024 und ex Kapitalmassnahme am 26.04.2024 The instrument AB2 NL0011540547 ABN AMRO BANK DR/EO1... ► Artikel lesen | |
| 10.04. | AlzeCure Pharma: Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board | 2.267 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / April 10, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB ("AlzeCure" or "the Company"), a pharmaceutical company that develops candidate drugs for CNS... ► Artikel lesen | |
| 04.04. | AlzeCure Pharma Publishes its Annual Report for 2023 | 186 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / April 4, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule... ► Artikel lesen | |
| 03.04. | AlzeCure Pharma: AlzeCure Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024 | 215 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / April 3, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 14.03. | AlzeCure Pharma: AlzeCure to Partake in Redeye Theme: Alzheimer on March 21 | 244 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / March 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drug candidates... ► Artikel lesen | |
| 07.03. | AlzeCure Pharma: AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference | 528 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / March 7, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops small molecule drug candidates... ► Artikel lesen | |
| 05.03. | AlzeCure Pharma: AlzeCure Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's | 397 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / March 5, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drug candidates... ► Artikel lesen | |
| 29.02. | AlzeCure Pharma: AlzeCure's Alzheimer's Project NeuroRestore ACD856 is Granted an Additional Patent | 299 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / February 29, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for CNS... ► Artikel lesen | |
| 27.02. | AlzeCure Pharma: AlzeCure Publishes its Year-end Report for January - December 2023 | 306 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / February 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January -... ► Artikel lesen | |
| 12.02. | AlzeCure Pharma Broadcasts Live Expert Event on Alzheimer's Around Highly Current Gamma-Secretase Modulators | 256 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / February 12, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 06.02. | AlzeCure Pharma: AlzeCure Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference | 886 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / February 6, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 31.01. | AlzeCure Pharma: AlzeCure CEO Martin Jönsson to Present at the International Investor Conference BioCapitalEurope | 536 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / January 31, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 29.01. | AlzeCure Selects Promising Drug Candidate ACD137 | 2 | Contract Pharma | ||
| 29.01. | AlzeCure Pharma: AlzeCure Selects Drug Candidate and Enters Next Phase of Development with TrkA-NAM ACD137 against Severe Pain | 343 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / January 29, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR, a pharmaceutical company that develops a broad portfolio of small... ► Artikel lesen | |
| 17.01. | The Government Draws Attention to Swedish Alzheimer's Research and Together with the Swedish Alzheimer's Foundation Visit AlzeCure Pharma | 398 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / January 17, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 07.12.23 | AlzeCure Pharma: AlzeCure Presents at Redeye Investor Forum in Göteborg on December 14 | 284 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / December 07, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule... ► Artikel lesen | |
| 28.11.23 | AlzeCure Pharma: AlzeCure Presents at DNB Nordic-American Healthcare Conference in New York December 6-7 | 261 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small... ► Artikel lesen | |
| 22.11.23 | AlzeCure Pharma: AlzeCure presents at Stora Aktiedagarna on November 27 | 298 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / November 22, 2023 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 392,30 | -0,08 % | Vertex Pharmaceuticals Inc. Q1 Profit Increases, beats estimates | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) reported a profit for its first quarter that increased from last year and beat the Street estimates.The company's bottom... ► Artikel lesen | |
| VIATRIS | 10,425 | +0,58 % | Viatris-Aktie: Kurs heute im Minus (10,4823 €) | Im Minus liegt aktuell die Viatris-Aktie . Zuletzt zahlten Investoren für das Papier 11,30 US-Dollar. Am Aktienmarkt liegt das Wertpapier von Viatris zur Stunde im Minus. Die Aktie verbilligte sich... ► Artikel lesen | |
| OPKO HEALTH | 1,154 | -2,52 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results | MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights... ► Artikel lesen | |
| JAGUAR HEALTH | 0,270 | -0,22 % | Jaguar Health, Inc.: Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease and Short Bowel Syndrome in Europe | Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS SAN FRANCISCO, CA / ACCESSWIRE / May... ► Artikel lesen | |
| ALTIMMUNE | 6,743 | +0,52 % | Altimmune, Inc: Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update | Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,266 | +0,64 % | SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level | - The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential - - 100% Overall Response... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 4,706 | +0,88 % | On behalf of Lucien Selce: Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value | Outlines Concerns Regarding the Company's Current Strategy and Board Composition and Offers Superior Paths to Improving Performance and Market Penetration
Lucien Selce, who owns approximately 2.2%... ► Artikel lesen | |
| DMK PHARMACEUTICALS | 0,049 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 2 | The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameLU0102219945 G.SACHS... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 0,412 | -1,20 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease | Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024Phase 2 clinical trial for KIO-104 for retinal inflammation... ► Artikel lesen | |
| LIPOCINE | 5,320 | +1,72 % | Lipocine Inc.: Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 | SALT LAKE CITY, May 9, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024 and provided... ► Artikel lesen | |
| PHOTOCURE | 4,965 | +0,81 % | Photocure: Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024 | OSLO, Norway, May 7, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the AUA 2024:... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,153 | +5,64 % | Earnings call: Aclaris Therapeutics progresses with atopic dermatitis study | ||
| SOLID BIOSCIENCES | 10,390 | +0,48 % | Solid Biosciences Inc.: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 14,560 | -0,14 % | Eurobio Scientific: Fiscal Year 2023, Strategic Transformation Of The Group | FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP Continued total year growth in core business revenues, up 39%Successful deployment of the Group's strategy: Proprietary products up at 30% of... ► Artikel lesen | |
| MEDICURE | 0,710 | 0,00 % | Medicure, Inc.: Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency | WINNIPEG, MB / ACCESSWIRE / April 23, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and... ► Artikel lesen |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
